Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) has announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $10.25 per share.

All of the shares in the offering will be sold by Achillion. The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $115.3 million.

The offering is expected to close on February 18, 2015, subject to customary closing conditions.

Leerink Partners LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers, Wells Fargo Securities, LLC is acting as lead manager, and JMP Securities LLC is acting as co-manager for the offering.